ZNF503 and glioma: Enrichment analysis of these DEGs in PaGenBase showed that DEGs were highly expressed in tissues with a high distribution of peripheral immune cells, such as blood and spleen, suggesting that ZNF503-AS2 may influence glioma progression by promoting immune cell infiltration into the tumor (Fig 2F).